BOARD OF DIRECTORS

John A. Orwin

John A. Orwin has served as a director of Travere Therapeutics since March 2017. Since April 2018, Mr. Orwin has served as the president and chief executive officer of Atreca, Inc., a biopharmaceutical company. From June 2013 through June 2017, Mr. Orwin served as chief executive officer of Relypsa, Inc. and from June 2013 through March 2017 also served as president of Relypsa and served on its board of directors from June 2013 until Relypsa’s acquisition by the Galenica Group in September 2016. Prior to Relypsa, Mr. Orwin served as president and chief operating officer of Affymax, Inc., a biotechnology company, from April 2010 to January 2011, and as Affymax’s chief executive officer and a member of the board of directors from February 2011 to May 2013. Previously, Mr. Orwin served as vice president and then senior vice president of the BioOncology Business Unit at Genentech, Inc. (now a member of the Roche Group), a biotechnology company, and served in various executive-level positions at Johnson & Johnson, a life sciences company. Prior to such roles, Mr. Orwin held senior marketing and sales positions at various life sciences and pharmaceutical companies, including Alza Corporation (acquired by Johnson & Johnson), SangStat Medical Corporation (acquired by Genzyme), Rhone-Poulenc Rorer Pharmaceuticals, Inc. (merged with Sanofi-Aventis) and Schering-Plough Corporation (merged with Merck). Mr. Orwin currently serves as the chair of the board of directors of CARGO Therapeutics (formerly Syncopation Life Sciences), a biotechnology company, and as the chair of the board of directors for AnaptysBio, Inc., a clinical-stage biotechnology company, and as the chair of the board of directors of the privately held company Nested Therapeutics which is focused on precision oncology medicine. Previously, Mr. Orwin served as a member of the board of directors of Seagen Inc. from January 2014 to December 2023, the board of directors of NeurogesX, Inc., and on the board of directors of Array BioPharma Inc. from November 2012 until its acquisition by Pfizer in July of 2019. Mr. Orwin received a B.A. in economics from Rutgers University and an M.B.A. from New York University